Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
16.72
-0.01 (-0.06%)
At close: Dec 24, 2025, 4:00 PM EST
16.91
+0.18 (1.08%)
Pre-market: Dec 26, 2025, 6:38 AM EST
Enliven Therapeutics Employees
Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.
Employees
62
Change (1Y)
16
Growth (1Y)
34.78%
Revenue / Employee
n/a
Profits / Employee
-$1,567,855
Market Cap
992.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELVN News
- 14 days ago - Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PRNewsWire
- 14 days ago - Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PRNewsWire
- 5 weeks ago - Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
- 6 weeks ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
- 4 months ago - Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting - PRNewsWire
- 4 months ago - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - PRNewsWire
- 6 months ago - Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 6 months ago - Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire